Home
Our Team
- About
Technology
Pipeline
Partnerships
Newsroom
- Events
Careers
Contact

Select Page

VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine

News & Updates

HELLO WORLD

ILLUSTRATOR

WRITER

WEB-DESIGNER

VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine

Jun 5, 2018

View/Download ASCO 2018 Poster

Search for:

Recent Posts

Associate Scientist Viral Vector QC
Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
Vaccitech Appoints Two Independent Board Directors

Archives

Vaccitech Limited

The Schrödinger Building
Heatley Road
The Oxford Science Park
Oxford
OX4 4GE

T: +44 (0)1865 818808

Home
About
Sitemap
Privacy Policy
Privacy Notice
Careers
Contact

Vaccitech is a T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer

Twitter
LinkedIn

© Vaccitech 2021 All rights reserved. Website by Brand Cooke